| 引用本文: |
范彩虹, 吴玉, 李蘩漪, 姚梓平, 金晶.益气固表丸对COPD稳定期（肺脾气虚证）患者外周血有核细胞线粒体膜电位及细胞内活性氧的影响[J].湖南中医药大学学报,2026,46(9):1921-1927[点击复制] |
|
| |
|
|
| 本文已被：浏览 52次 下载 58次 |
| 益气固表丸对COPD稳定期（肺脾气虚证）患者外周血有核细胞线粒体膜电位及细胞内活性氧的影响 |
| 范彩虹,吴玉,李蘩漪,姚梓平,金晶 |
| (新疆医科大学第一附属医院中医综合科, 新疆 乌鲁木齐 830011) |
| 摘要: |
| 目的 观察益气固表丸用于慢性阻塞性肺疾病（COPD）肺脾气虚证患者的临床疗效及对线粒体功能的影响。方法 纳入2024年1月—2025年6月新疆医科大学第一附属医院收治的COPD稳定期（肺脾气虚证）患者90例，按中心分层随机法分组，分别设为西药组、安慰剂组、益气固表丸组，每组30例。西药组接受西医基础治疗[吸入舒利迭（50 μg沙美特罗/250 μg丙酸氟替卡松，1吸/次，2次/d）]；安慰剂组给予西医基础治疗+益气固表丸模拟剂（10粒/次，3次/d）；益气固表丸组给予西医基础治疗+益气固表丸（10粒/次，3次/d）。持续治疗12周后，评价3组临床疗效；比较3组患者干预前后的中医证候积分、肺功能指标[用力肺活量（FVC）、第一秒用力呼气容积（FEV1）、第一秒用力呼气容积占预计值百分比（FEV1% pred）]、改良英国医学研究委员会呼吸困难量表（mMRC）评分及COPD评估测试（CAT）评分的变化。采集患者外周血并分离有核细胞，采用流式细胞术检测细胞线粒体膜电位（MMP）与胞内活性氧（ROS）水平。结果 治疗12周后，益气固表丸组临床总有效率高于西药组和安慰剂组（P＜0.05）；与西药组、安慰剂组相比，益气固表丸组中医证候积分、mMRC评分、CAT评分及外周血ROS水平降低，FVC、FEV1、FEV1% pred及外周血有核细胞MMP水平均升高（P＜0.05）。结论 益气固表丸治疗COPD稳定期（肺脾气虚证）患者疗效显著，可明显减轻患者临床症状，改善肺功能和生活品质，其机制可能与改善线粒体功能、减少ROS产生相关。 |
| 关键词: 慢性阻塞性肺疾病|益气固表丸|肺脾气虚|线粒体膜电位|活性氧 |
| DOI：10.3969/j.issn.1674-070X.2026.09.025 |
| 投稿时间：2026-05-21 |
| 基金项目:新疆医科大学第一附属医院“青年科研启航”专项基金(2023YFY-QKQN-57)。 |
|
| Effects of Yiqi Gubiao Pill on mitochondrial membrane potential and intracellular reactive oxygen species in peripheral blood nucleated cells of patients with stable COPD of lung-spleen qi deficiency pattern |
| FAN Caihong, WU Yu, LI Fanyi, YAO Ziping, JIN Jing |
| (Department of General Traditional Chinese Medicine, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, China) |
| Abstract: |
| Objective To observe the clinical efficacy of Yiqi Gubiao Pill (YQGBP) in patients with chronic obstructive pulmonary disease (COPD) of lung-spleen qi deficiency pattern and its effect on mitochondrial function. Methods Ninety patients with stable COPD (lung-spleen qi deficiency pattern) admitted to The First Affiliated Hospital of Xinjiang Medical University from January 2024 to June 2025 were enrolled and divided by central stratified randomization into a Western medicine group, a placebo group, and a YQGBP group, with 30 patients in each group. The Western medicine group received basic Western medicine treatment [inhaled Seretide (50 μg salmeterol/250 μg fluticasone propionate, 1 inhalation/time, 2 times/d)]; the placebo group received basic Western medicine treatment plus a matching placebo of YQGBP (10 pills/time, 3 times/d); the YQGBP group received basic Western medicine treatment plus YQGBP (10 pills/time, 3 times/d). After 12 weeks of continuous treatment, the clinical efficacy of the three groups was evaluated, and the changes in TCM pattern scores, pulmonary function indicators [forced vital capacity (FVC), forced expiratory volume in one second (FEV1), forced expiratory volume in one second as a percentage of predicted value (FEV1%pred)], modified Medical Research Council (mMRC) dyspnea scale scores, and COPD Assessment Test (CAT) scores were compared before and after intervention. Peripheral blood was collected and nucleated cells were isolated, and flow cytometry was used to detect the levels of mitochondrial membrane potential (MMP) and intracellular reactive oxygen species (ROS). Results After 12 weeks of treatment, the total clinical effective rate of the YQGBP group was higher than that of the Western medicine group and the placebo group (P<0.05); compared with the Western medicine group and the placebo group, the TCM pattern scores, mMRC scores, CAT scores, and peripheral blood ROS levels of the YQGBP group were decreased, while the levels of FVC, FEV1, FEV1%pred, and peripheral blood MMP were increased (P<0.05). Conclusion YQGBP shows significant efficacy in the treatment of patients with stable COPD (lung-spleen qi deficiency pattern), markedly alleviating the clinical symptoms and improving pulmonary function and quality of life; its mechanism may be related to improving mitochondrial function and reducing ROS production. |
| Key words: chronic obstructive pulmonary disease|Yiqi Gubiao Pill|lung-spleen qi deficiency|mitochondrial membrane potential|reactive oxygen species |
|
二维码（扫一下试试看！） |
|
|
|
|
